Adoptive Transfer of Donor T-cells Overview
Adoptive transfer of donor T-cells is a form of immunotherapy in which T lymphocytes are isolated from a donor, expanded or modified ex vivo, and then infused into a recipient to restore or enhance immune function. This approach leverages the specificity and potency of the adaptive immune response by providing patients with functional effector/memory populations that may otherwise be absent or dysfunctional due to disease or treatment effects. It is used to treat diseases such as cancer, viral infections, and immune deficiencies.
Mechanism of Action
Donor T-cells recognize and eliminate target cells expressing specific antigens (e.g., tumor-associated antigens or viral antigens). CD4+ T cells provide help for antibody production and CD8+ T cells mediate direct cytotoxicity.
Biological Functions
Disease Associations
Safety Considerations
- Graft-versus-host disease (GVHD)
- Cytokine release syndrome (CRS)
- On-target, off-tumor toxicity
- Neurotoxicity
- B cell aplasia (for CD19-targeted CAR-T cells)
- Insertional mutagenesis (for gene-modified T-cells)
Interacting Drugs
Associated Biomarkers
Biomarker |
---|
TCR repertoire |
CAR expression levels |
Cytokine production (e.g., IFN-gamma, TNF-alpha) |
Persistence of transferred T-cells |
Tumor regression (in cancer therapy) |
Viral load (in viral infections) |
GVHD markers (e.g., skin rash, liver enzyme elevation) |